The Efficacy of Prolonged Antibiotic Therapy for the Prevention of Relapsing Peritonitis in Peritoneal Dialysis Patients With High Dialysis Effluent Bacterial DNA Fragment Levels

Sponsor
Chinese University of Hong Kong (Other)
Overall Status
Completed
CT.gov ID
NCT02593201
Collaborator
(none)
358
1
2
40.1
8.9

Study Details

Study Description

Brief Summary

Peritoneal dialysis (PD) is the first-line treatment of end stage renal disease (ESRD) in Hong Kong. Despite the advances in antibiotic therapy and connecting system, recurrent peritonitis remains the major cause of peritoneal failure. A recent study showed that an elevated bacterial DNA fragment levels in PD effluent 5 days prior to the completion of antibiotics predicts the development of relapsing or recurrent peritonitis episodes. We hypothesize that prolonged antibiotic therapy in PD patients with peritonitis and high PD effluent bacterial DNA fragment levels could prevent the development of relapsing and recurrent peritonitis. We plan to conduct a randomized control study of 360 patients with PD peritonitis. After inform consent, they will be randomized to receive one additional week of the effective antibiotic treatment (the Preemptive Treatment Group) or no additional treatment (the Control Group). Specimens of PD effluent will be collected 5 days prior to the completion of antibiotics for the measurement of bacterial DNA fragments. All patients will be followed for 6 months after completion of antibiotic therapy for the development of relapsing, recurrent, or repeat peritonitis episodes. Our study will determine the efficacy of a test-before-treat algorithm that could reduce the incidence of relapsing and recurrent peritonitis and, at the same time, minimize the unnecessary use of prolonged antibiotic treatment.

Condition or Disease Intervention/Treatment Phase
  • Drug: Extended antibiotics (cefazolin or ceftazidime)
  • Drug: Usual antibiotics (cefazolin or ceftazidime)
Phase 4

Study Design

Study Type:
Interventional
Actual Enrollment :
358 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Prevention
Actual Study Start Date :
Feb 26, 2016
Actual Primary Completion Date :
Dec 31, 2018
Actual Study Completion Date :
Jun 30, 2019

Arms and Interventions

Arm Intervention/Treatment
Experimental: Treatment

One extra week of antibiotic therapy

Drug: Extended antibiotics (cefazolin or ceftazidime)
To continue with the existing effective antibiotic therapy for one extra week

Sham Comparator: Control

No extra antibiotics

Drug: Usual antibiotics (cefazolin or ceftazidime)
Usual duration of effective antibiotic therapy therapy

Outcome Measures

Primary Outcome Measures

  1. relapsing peritonitis episodes [6 months]

  2. repeat peritonitis episodes [6 months]

  3. recurrent peritonitis episodes [6 months]

Secondary Outcome Measures

  1. peritonitis that requires hospitalization [6 months]

  2. need of catheter removal [6 months]

    by record review

  3. need of conversion to long-term hemodialysis [6 months]

    by record review

  4. death due to peritonitis [6 months]

  5. all cause mortality [6 months]

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Patients with peritoneal dialysis-related peritonitis
Exclusion Criteria:
  • Patients with fungal peritonitis

  • Patients with obvious surgical problems and require laparotomy

Contacts and Locations

Locations

Site City State Country Postal Code
1 Department of Medicine & Therapeutics, Prince of Wales Hospital Shatin Hong Kong

Sponsors and Collaborators

  • Chinese University of Hong Kong

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Cheuk-Chun SZETO, Professor, Chinese University of Hong Kong
ClinicalTrials.gov Identifier:
NCT02593201
Other Study ID Numbers:
  • PPDNA
First Posted:
Nov 1, 2015
Last Update Posted:
Nov 13, 2019
Last Verified:
Nov 1, 2019

Study Results

No Results Posted as of Nov 13, 2019